These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12497581)

  • 1. Using splines to detect changes in PSA doubling times.
    Guess B; Jennrich R; Johnson H; Redheffer R; Scholz M
    Prostate; 2003 Feb; 54(2):88-94. PubMed ID: 12497581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical analysis of prostate-specific antigen doubling time calculation methodology.
    Svatek RS; Shulman M; Choudhary PK; Benaim E
    Cancer; 2006 Mar; 106(5):1047-53. PubMed ID: 16456812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
    Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
    J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy.
    Shimizu F; Matsuyama Y; Tominaga T; Ohashi Y; Fujime M
    Urol Int; 2007; 79(4):356-60. PubMed ID: 18025856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy.
    Ross RW; Manola J; Hennessy K; Galsky M; Scher H; Small E; Kelly WK; Kantoff PW
    Clin Cancer Res; 2005 Jul; 11(14):5195-8. PubMed ID: 16033836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hierarchical changepoint models for biochemical markers illustrated by tracking postradiotherapy prostate-specific antigen series in men with prostate cancer.
    Bellera CA; Hanley JA; Joseph L; Albertsen PC
    Ann Epidemiol; 2008 Apr; 18(4):270-82. PubMed ID: 18374279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
    Shulman MJ; Karam JA; Benaim EA
    Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.
    Valicenti RK; DeSilvio M; Hanks GE; Porter A; Brereton H; Rosenthal SA; Shipley WU; Sandler HM;
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1064-71. PubMed ID: 16979837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation rescue for biochemical failure after surgery for prostate cancer: predictive parameters and an assessment of contemporary predictive models.
    Symon Z; Kundel Y; Sadetzki S; Oberman B; Ramon J; Laufer M; Catane R; Pfeffer MR
    Am J Clin Oncol; 2006 Oct; 29(5):446-50. PubMed ID: 17023777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radical prostatectomy for clinical stage T3a disease.
    Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
    Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [PSA and follow-up after treatment of prostate cancer].
    Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
    Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy.
    Pinover WH; Horwitz EM; Hanlon AL; Uzzo RG; Hanks GE
    Cancer; 2003 Feb; 97(4):1127-33. PubMed ID: 12569615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PSA doubling time kinetics during prostate cancer biochemical relapse after external beam radiation therapy.
    Bates AT; Pickles T; Paltiel C
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):148-53. PubMed ID: 15850915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSA doubling time post radiation: the effect of neoadjuvant androgen ablation.
    Tyldesley S; Coldman A; Pickles T;
    Can J Urol; 2004 Aug; 11(4):2316-21. PubMed ID: 15460601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
    Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
    Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of short postoperative prostate-specific antigen doubling time for patients diagnosed during PSA era.
    Lin DD; Schultz D; Renshaw AA; Rubin MA; Richie JP; D'Amico AV
    Urology; 2005 Mar; 65(3):528-32. PubMed ID: 15780370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.
    Ciezki JP; Reddy CA; Garcia J; Angermeier K; Ulchaker J; Mahadevan A; Chehade N; Altman A; Klein EA
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):512-7. PubMed ID: 16213667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.